ADMA

$0.00

(

0.00%

)
Quote details

stock

ADMA Biologics Inc

NASDAQ | ADMA

19.93

USD

$0.00

(

0.00%

)

At Close (As of Dec 12, 2025)

$4.86B

Market Cap

23.7

P/E Ratio

0.86

EPS

$25.67

52 Week High

$13.50

52 Week Low

HEALTHCARE

Sector

ADMA Chart

Recent Chart
Price Action

ADMA Technicals

Tags:

ADMA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $220M
Total Revenue $426M
Cost Of Revenue $207M
Costof Goods And Services Sold $207M
Operating Income $139M
Selling General And Administrative $74M
Research And Development $1.8M
Operating Expenses $81M
Investment Income Net -
Net Interest Income -$12M
Interest Income $2.1M
Interest Expense $14M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $8M
Income Before Tax $126M
Income Tax Expense -$72M
Interest And Debt Expense -
Net Income From Continuing Operations $198M
Comprehensive Income Net Of Tax -
Ebit $140M
Ebitda $148M
Net Income $198M

Revenue & Profitability

Earnings Performance

ADMA Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $489M
Total Current Assets $331M
Cash And Cash Equivalents At Carrying Value $103M
Cash And Short Term Investments $103M
Inventory $170M
Current Net Receivables $50M
Total Non Current Assets $157M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $460K
Intangible Assets Excluding Goodwill $460K
Goodwill $3.5M
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $8M
Other Non Current Assets -
Total Liabilities $140M
Total Current Liabilities $56M
Current Accounts Payable $20M
Deferred Revenue -
Current Debt -
Short Term Debt $1.2M
Total Non Current Liabilities $84M
Capital Lease Obligations $9.8M
Long Term Debt $72M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $82M
Other Current Liabilities $30M
Other Non Current Liabilities $1.7M
Total Shareholder Equity $349M
Treasury Stock -
Retained Earnings -$309M
Common Stock $24K
Common Stock Shares Outstanding $243M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow $119M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $8M
Capital Expenditures $8.6M
Change In Receivables -
Change In Inventory $2.7M
Profit Loss -
Cashflow From Investment -$8.6M
Cashflow From Financing -$58M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $198M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $220M
Total Revenue $426M
Cost Of Revenue $207M
Costof Goods And Services Sold $207M
Operating Income $139M
Selling General And Administrative $74M
Research And Development $1.8M
Operating Expenses $81M
Investment Income Net -
Net Interest Income -$12M
Interest Income $2.1M
Interest Expense $14M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $8M
Income Before Tax $126M
Income Tax Expense -$72M
Interest And Debt Expense -
Net Income From Continuing Operations $198M
Comprehensive Income Net Of Tax -
Ebit $140M
Ebitda $148M
Net Income $198M

ADMA News

ADMA Profile

ADMA Biologics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

ADMA Biologics, Inc. is a biopharmaceutical company based in Ramsey, New Jersey, specializing in the development and commercialization of plasma-derived therapies for immunodeficiencies and infectious diseases. The company employs proprietary production technologies to produce high-quality therapeutic products, thereby enhancing patient outcomes in a significant healthcare market. With a strong pipeline and a dedication to addressing critical medical needs, ADMA is well-positioned for growth in the evolving landscape of biopharmaceuticals.

LPTX
+368.57%
$2.05
PAVS
+22.02%
$0.04
YGMZ
-61.42%
$0.02
KIND
+9.48%
$2.77
NVDA
-2.33%
$176.70
WOK
-22.08%
$0.13
AXDX
-61.36%
$0.03
F
+1.64%
$13.63
ATPC
-20.66%
$0.14
KAVL
-15.50%
$0.16
ADAP
-15.14%
$0.05
RIVN
+15.94%
$19.05
CGC
+23.00%
$1.39
AKAN
+28.68%
$1.01
TLRY
+29.53%
$10.92
SOND
-23.45%
$0.12
OCG
+58.12%
$1.44
TSLA
-0.48%
$444.70
ZDGE
+60.49%
$3.90
RMBL
+60.50%
$3.21
AVGO
-11.40%
$360.03
NIO
+1.98%
$5.13
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
PFE
+0.07%
$25.80
SRM
+53.27%
$10.30
PLTD
+0.15%
$6.32
ASST
-1.30%
$0.90
CDE
+9.45%
$17.48
SNAP
-3.53%
$7.64
MTSR
-0.35%
$70.50
BBD
+2.71%
$3.41
FI
+2.38%
$68.16
VIVK
+9.45%
$0.08
APLT
-44.62%
$0.12
FRMI
-39.81%
$9.17
HBAN
+1.99%
$17.91
CCL
+5.93%
$27.84
TE
-11.09%
$5.21
AFMD
-34.94%
$0.18
UBER
+1.52%
$85.44
KO
-1.56%
$69.11
WULF
+0.44%
$15.83
SOUN
-1.47%
$12.03
EXK
+4.20%
$9.41
CAN
-1.75%
$0.92
EOSE
+11.15%
$16.44
TWOH
0.00%
$0.00
INTC
-0.51%
$39.30
DRCT
-11.02%
$0.07
MSTR
-0.72%
$183.30
GRYP
-10.38%
$1.38
MU
-1.99%
$258.46
MODV
-25.22%
$0.43
CX
+2.94%
$11.19
ASBP
+4.78%
$0.10
RR
-8.54%
$4.28
ITUB
+2.39%
$7.27
PLUG
0.00%
$2.35
NVVE
-35.89%
$0.10
RZLT
+14.28%
$1.60
MDLZ
-0.18%
$53.79
ONDS
-0.83%
$8.94
NVTS
+0.65%
$9.18
TSM
-1.44%
$304.85
BMNR
-4.27%
$36.74
CLSK
-2.80%
$14.40
CPNG
-0.76%
$25.86
SHOT
-74.37%
$0.39
ZAPP
-46.30%
$0.15
RXRX
-3.98%
$4.58
QUBT
+2.14%
$12.83
VALE
-4.74%
$12.65
IVP
-5.46%
$0.05
ET
-0.24%
$16.41
HL
-2.76%
$18.81
ORCL
-3.57%
$191.74
NBIS
+0.73%
$94.28
PG
+0.67%
$140.76
SPR
+0.22%
$39.50
FSM
+2.51%
$9.78
KMI
+0.86%
$26.82
C
+0.58%
$111.74
HOOD
-0.81%
$122.37
PLTR
-3.53%
$180.90
PPBT
-0.44%
$0.82
CVE
-0.78%
$17.72
HPQ
+0.86%
$25.41
SONN
-59.35%
$1.26
ABEV
+0.42%
$2.51
HIMS
-0.29%
$37.77
BMNU
-7.43%
$9.45
USB
+0.03%
$53.58
CSX
+0.16%
$37.15
XPEV
-2.34%
$19.19
LULU
-0.32%
$187.01
FITB
+1.76%
$48.39
WIT
-2.07%
$2.83
GM
+0.06%
$80.85
T
+1.91%
$24.76
LPTX
+368.57%
$2.05
PAVS
+22.02%
$0.04
YGMZ
-61.42%
$0.02
KIND
+9.48%
$2.77
NVDA
-2.33%
$176.70
WOK
-22.08%
$0.13
AXDX
-61.36%
$0.03
F
+1.64%
$13.63
ATPC
-20.66%
$0.14
KAVL
-15.50%
$0.16
ADAP
-15.14%
$0.05
RIVN
+15.94%
$19.05
CGC
+23.00%
$1.39
AKAN
+28.68%
$1.01
TLRY
+29.53%
$10.92
SOND
-23.45%
$0.12
OCG
+58.12%
$1.44
TSLA
-0.48%
$444.70
ZDGE
+60.49%
$3.90
RMBL
+60.50%
$3.21
AVGO
-11.40%
$360.03
NIO
+1.98%
$5.13
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
PFE
+0.07%
$25.80
SRM
+53.27%
$10.30
PLTD
+0.15%
$6.32
ASST
-1.30%
$0.90
CDE
+9.45%
$17.48
SNAP
-3.53%
$7.64
MTSR
-0.35%
$70.50
BBD
+2.71%
$3.41
FI
+2.38%
$68.16
VIVK
+9.45%
$0.08
APLT
-44.62%
$0.12
FRMI
-39.81%
$9.17
HBAN
+1.99%
$17.91
CCL
+5.93%
$27.84
TE
-11.09%
$5.21
AFMD
-34.94%
$0.18
UBER
+1.52%
$85.44
KO
-1.56%
$69.11
WULF
+0.44%
$15.83
SOUN
-1.47%
$12.03
EXK
+4.20%
$9.41
CAN
-1.75%
$0.92
EOSE
+11.15%
$16.44
TWOH
0.00%
$0.00
INTC
-0.51%
$39.30
DRCT
-11.02%
$0.07
MSTR
-0.72%
$183.30
GRYP
-10.38%
$1.38
MU
-1.99%
$258.46
MODV
-25.22%
$0.43
CX
+2.94%
$11.19
ASBP
+4.78%
$0.10
RR
-8.54%
$4.28
ITUB
+2.39%
$7.27
PLUG
0.00%
$2.35
NVVE
-35.89%
$0.10
RZLT
+14.28%
$1.60
MDLZ
-0.18%
$53.79
ONDS
-0.83%
$8.94
NVTS
+0.65%
$9.18
TSM
-1.44%
$304.85
BMNR
-4.27%
$36.74
CLSK
-2.80%
$14.40
CPNG
-0.76%
$25.86
SHOT
-74.37%
$0.39
ZAPP
-46.30%
$0.15
RXRX
-3.98%
$4.58
QUBT
+2.14%
$12.83
VALE
-4.74%
$12.65
IVP
-5.46%
$0.05
ET
-0.24%
$16.41
HL
-2.76%
$18.81
ORCL
-3.57%
$191.74
NBIS
+0.73%
$94.28
PG
+0.67%
$140.76
SPR
+0.22%
$39.50
FSM
+2.51%
$9.78
KMI
+0.86%
$26.82
C
+0.58%
$111.74
HOOD
-0.81%
$122.37
PLTR
-3.53%
$180.90
PPBT
-0.44%
$0.82
CVE
-0.78%
$17.72
HPQ
+0.86%
$25.41
SONN
-59.35%
$1.26
ABEV
+0.42%
$2.51
HIMS
-0.29%
$37.77
BMNU
-7.43%
$9.45
USB
+0.03%
$53.58
CSX
+0.16%
$37.15
XPEV
-2.34%
$19.19
LULU
-0.32%
$187.01
FITB
+1.76%
$48.39
WIT
-2.07%
$2.83
GM
+0.06%
$80.85
T
+1.91%
$24.76

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.